PM
RYTM icon

Prosight Management’s Rhythm Pharmaceuticals RYTM Stock Holding History

Prosight Management’s Portfolio RYTM Stock Details RYTM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q4 		– Sell
-80,000
Closed -$1.96M – 51
2022
Q3 		$1.96M Buy
+80,000
New +$1.49M 1.05% 25

Other funds holding RYTM

Primecap Management
Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Alkeon Capital Management
Alkeon Capital Management New York $59.5B AUM 51.63% 1-Year Est. Return

Prosight Management's RYTM Position: Q4 2022 in Review

Prosight Management sold out of Rhythm Pharmaceuticals (RYTM) in Q4 2022, closing a stake of 80,000 shares — an estimated $1.96M sold.

Prosight Management first reported a position in RYTM in Q3 2022 and held it in 1 quarter. The position peaked at $1.96M in Q3 2022. 115 funds tracked by Wall St. Rank hold RYTM as of Q4 2022.

  • Prosight Management reported no remaining Rhythm Pharmaceuticals position as of Q4 2022 after selling out during the quarter.
  • Prosight Management sold 80,000 Rhythm Pharmaceuticals shares in Q4 2022, an estimated $1.96M.
  • Prosight Management first reported a position in Rhythm Pharmaceuticals in Q3 2022 and held it in 1 quarter.
  • Prosight Management's Rhythm Pharmaceuticals position peaked at $1.96M in Q3 2022.
  • 115 funds tracked by Wall St. Rank held Rhythm Pharmaceuticals as of Q4 2022.

Based on Prosight Management's 13F filing for Q4 2022, filed 14 Feb 2023.